Comprehensive panels
Revealing a detailed picture
For cancer patients and individuals with a family history of multiple cancers, in-depth genetic testing can determine whether the cancer is hereditary in origin. Our comprehensive hereditary cancer panels use next-generation sequencing to evaluate dozens of genes for personalized insights into whether an individual carries a heritable, elevated risk for cancer. Patients identified with a hereditary cancer syndrome can benefit from directed treatment choices, personalized surveillance, and understanding of their cancer risks.
Comprehensive panel test menu
Comprehensive panel
Key testing
- XCP | Hereditary Expanded Cancer Panel, Varies
- Assesses 87 genes associated with an increased risk of a variety of cancers, including breast cancer, colon cancer, gastric cancer, paragangliomas, pheochromocytomas, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, thyroid cancer, endometrial cancer, and Wilms tumor.
- Helps identify patients with common and rare hereditary cancer syndromes when the patient has a variety of cancers in their personal or family history.
- COMCP | Hereditary Common Cancer Panel, Varies
- Assesses 36 genes associated with an increased risk for common cancers, including breast, colon, gastric, ovarian, pancreatic, prostate, skin, thyroid, endometrial, and polyposis.
- Helps identify patients with common hereditary cancer syndromes when the patient has multiple cancers in their personal or family history.
- Upon request, this test reflexes to Panel to Whole Exome Sequencing Reflex Test, Varies (Mayo ID: WESPR).
Highlights
Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant genes, the panels provide clarity on diagnosis, prognosis, and treatment approaches.